Yüklüyor......
Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis
IMPORTANCE: The optimum duration of adjuvant trastuzumab among patients with early breast cancer is uncertain but of great therapeutic relevance. OBJECTIVE: To compare shorter durations with 1 year of adjuvant trastuzumab for patients with early breast cancer. DATA SOURCES: PubMed, Embase, Cochrane...
Kaydedildi:
| Yayımlandı: | JAMA Netw Open |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Medical Association
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7445596/ https://ncbi.nlm.nih.gov/pubmed/32833018 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.11777 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|